



IMMUNIZATION RECORD

PART I – TO BE COMPLETED BY STUDENT

Name \_\_\_\_\_  
Last First Middle

Address \_\_\_\_\_  
Street City State Zip

Date of Entry \_\_\_/\_\_\_/\_\_\_ Date of Birth \_\_\_/\_\_\_/\_\_\_ Longwood ID# \_\_\_\_\_

Status: Full-time \_\_\_\_\_ Part-time \_\_\_\_\_ Undergraduate \_\_\_\_\_

\_\_\_ Immunization Religious Exemption – enclose notarized certificate from your state health department with completed Tuberculosis Screening

\*\*\*PERMISSION TO TREAT\*\*\* (If you are under 18 when entering, your parent/guardian must sign below in order for you to be seen at the SHC.)

I hereby authorize the clinicians of Longwood University Student Health Center to examine, interview, test and treat the above named student as they may deem advisable and to disclose such information to other responsible University officials as necessary.

Signature \_\_\_\_\_ Date \_\_\_\_\_

PART II – TO BE COMPLETED AND SIGNED BY YOUR HEALTH CARE PROVIDER (all information must be in English)

\*\*Healthcare Provider: Please fill in the dates of immunization. Placing “see attached” or simply attaching a copy of the immunization record is not permitted.

MEDICAL EXEMPTION

\_\_\_DPT \_\_\_Td \_\_\_OPV \_\_\_Measles \_\_\_Rubella \_\_\_Mumps

As specified in Section 22.1-271.2, C (II) of the Code. I certify that administration of the vaccine(s) designated above would be detrimental to this student’s health. The vaccine(s) is (are) specifically contraindicated because \_\_\_\_\_

This contraindication is \_\_\_permanent (or) \_\_\_temporary and expected to preclude immunization until \_\_\_/\_\_\_/\_\_\_

REQUIRED IMMUNIZATIONS (Record as Month/Day/Year)

A. MMR (MEASLES, MUMPS, RUBELLA) (Two doses required at least 28 days apart for students born after 1956)

Dose 1 given at age 12 months or later ..... #1 \_\_\_/\_\_\_/\_\_\_

Dose 2 given at least 28 days after first dose. .... #2 \_\_\_/\_\_\_/\_\_\_

B. POLIO (Primary series, doses at least 28 days apart with last dose after age 4 years. Three dose primary series is acceptable.)

OPV alone (oral Sabin three doses): #1 \_\_\_/\_\_\_/\_\_\_ #2 \_\_\_/\_\_\_/\_\_\_ #3 \_\_\_/\_\_\_/\_\_\_

IPV/OPV sequential: IPV #1 \_\_\_/\_\_\_/\_\_\_ IPV #2 \_\_\_/\_\_\_/\_\_\_ OPV #3 \_\_\_/\_\_\_/\_\_\_ OPV #4 \_\_\_/\_\_\_/\_\_\_

IPV alone (injected Salk four doses): #1 \_\_\_/\_\_\_/\_\_\_ #2 \_\_\_/\_\_\_/\_\_\_ #3 \_\_\_/\_\_\_/\_\_\_ #4 \_\_\_/\_\_\_/\_\_\_

C. TETANUS, DIPHTHERIA, PERTUSSIS

Primary series completed? Yes \_\_\_ No \_\_\_

Date of last dose in series: \_\_\_/\_\_\_/\_\_\_

Date of most recent booster dose: \_\_\_/\_\_\_/\_\_\_ (must be less than 10 years ago)

Type of booster: Td \_\_\_ Tdap \_\_\_ (Tdap booster recommended for ages 11-64 unless contraindicated)

Name: \_\_\_\_\_  
Last First Middle

DOB: \_\_\_\_/\_\_\_\_/\_\_\_\_  
M D Y

**D. HEPATITIS B** (Three doses of vaccine or two doses of adult vaccine in adolescents 11-15 years of age, or a positive hepatitis B surface antibody meets the requirement.) **Nursing and Athletic Training Students CANNOT Waive**

1. Immunization (hepatitis B)

a. Dose #1 \_\_\_\_/\_\_\_\_/\_\_\_\_ b. Dose #2 \_\_\_\_/\_\_\_\_/\_\_\_\_ c. Dose #3 \_\_\_\_/\_\_\_\_/\_\_\_\_  
Adult formulation \_\_\_\_ Child formulation \_\_\_\_ Adult formulation \_\_\_\_ Child formulation \_\_\_\_ Adult formulation \_\_\_\_ Child formulation \_\_\_\_

2. Immunization (combined hepatitis A and B vaccine)

a. Dose #1 \_\_\_\_/\_\_\_\_/\_\_\_\_ b. Dose #2 \_\_\_\_/\_\_\_\_/\_\_\_\_ c. Dose #3 \_\_\_\_/\_\_\_\_/\_\_\_\_

3. Hepatitis B surface antibody date \_\_\_\_/\_\_\_\_/\_\_\_\_ Result: Reactive \_\_\_\_ Non-reactive \_\_\_\_

**OR:** I have read the information on the website ([www.longwood.edu/health](http://www.longwood.edu/health)) and choose not to be vaccinated

\_\_\_\_\_  
Signature of student or guardian if waived

**E. MENINGOCOCCAL QUADRIVALENT** One or 2 doses for all college students with last dose on or after 16<sup>th</sup> birthday– revaccinate every 5 years if increased risk continues. **Nursing Students CANNOT Waive**

1. Quadrivalent conjugate (preferred; administer simultaneously with Tdap if possible).

a. Dose #1 \_\_\_\_/\_\_\_\_/\_\_\_\_ b. Dose #2 \_\_\_\_/\_\_\_\_/\_\_\_\_

2. Quadrivalent polysaccharide (acceptable alternative if conjugate not available).

Date \_\_\_\_/\_\_\_\_/\_\_\_\_

**OR:** I have read the information on the website ([www.longwood.edu/health](http://www.longwood.edu/health)) and choose not to be vaccinated

\_\_\_\_\_  
Signature of student or guardian if waived

**RECOMMENDED IMMUNIZATION (Record as Month/Day/Year)**

**F. VARICELLA** (Birth in the U.S. before 1980, a history of chicken pox, a positive varicella antibody, or two doses of vaccine meets the requirement.)

History of Disease: Yes \_\_\_\_ No \_\_\_\_ or Birth in U.S. before 1980 Yes \_\_\_\_ No \_\_\_\_

Varicella antibody \_\_\_\_/\_\_\_\_/\_\_\_\_ Result: Reactive \_\_\_\_ Non-reactive \_\_\_\_

Immunization

a. Dose #1 \_\_\_\_/\_\_\_\_/\_\_\_\_

b. Dose #2 \_\_\_\_/\_\_\_\_/\_\_\_\_ (given at least 12 wks. after first dose ages 1-12 yrs. and at least 4 weeks after first dose if age 13 yrs. or older)

**G. HUMAN PAPILLOMAVIRUS VACCINE (HPV2 or HPV4)** (3 doses of vaccine for students 11-26 yrs. of age at 0, 1/2, and 6m intervals) Immunization (indicate which preparation) Quadrivalent (HPV4) \_\_\_\_ or Bivalent (HPV2) \_\_\_\_

a. Dose #1 \_\_\_\_/\_\_\_\_/\_\_\_\_ b. Dose #2 \_\_\_\_/\_\_\_\_/\_\_\_\_ c. Dose #3 \_\_\_\_/\_\_\_\_/\_\_\_\_

**H. INFLUENZA**

Date of last dose: \_\_\_\_/\_\_\_\_/\_\_\_\_ Trivalent inactivated influenza vaccine (TIV) \_\_\_\_ Live attenuated influenza vaccine (LAIV) \_\_\_\_

**I. HEPATITIS A**

1. Immunization (hepatitis A)

a. Dose #1 \_\_\_\_/\_\_\_\_/\_\_\_\_ b. Dose #2 \_\_\_\_/\_\_\_\_/\_\_\_\_

2. Immunization (Combined hepatitis A and B vaccine)

a. Dose #1 \_\_\_\_/\_\_\_\_/\_\_\_\_ b. Dose #2 \_\_\_\_/\_\_\_\_/\_\_\_\_ c. Dose #3 \_\_\_\_/\_\_\_\_/\_\_\_\_

**J. PNEUMOCOCCAL POLYSACCHARIDE VACCINE** (One dose for members of high-risk group)

Date \_\_\_\_/\_\_\_\_/\_\_\_\_

Name: \_\_\_\_\_  
Last First Middle

DOB: \_\_\_\_/\_\_\_\_/\_\_\_\_  
M D Y

### PART III – TO BE COMPLETED BY STUDENT AND HEALTH CARE PROVIDER

#### Tuberculosis (TB) Screening/Risk Assessment for All Entering Students

**Student**, please answer the following questions:

1. Have you ever had a positive TB skin test?  Yes  No
2. Have you ever had close contact with anyone who was sick with TB?  Yes  No
3. Were you born in a country NOT listed below and arrived in the U.S. within the past 5 years?  Yes  No  
If YES what country? \_\_\_\_\_
4. Have you ever traveled\* to/in one or more country NOT listed below?  Yes  No  
If YES what country(ies)? \_\_\_\_\_
5. Have you ever been vaccinated with BCG?  Yes  No

Albania, Andorra, Antigua and Barbuda, Australia, Austria, Bahamas, Barbados, Belgium, British Virgin Islands, Canada, Chile, Costa Rica, Cuba, Cyprus, Czech Republic, Denmark, Dominica, Egypt, Fiji, Finland, France, Germany, Greece, Grenada, Hungary, Iceland, Iran (Islamic Republic of), Ireland, Israel, Italy, Jamaica, Jordan, Lebanon, Luxembourg, Malta, Mexico, Nauru, Netherlands, New Zealand, Norway, Oman, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Samoa, Saudi Arabia, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States of America, West Bank and Gaza Strip

**Health Care Provider:** Please review above and complete remainder of tuberculosis risk assessment (to be completed within six months of the start of classes). Individuals with any of the following are candidates for either tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented.

#### Risk Factor

1. Recent close contact with someone with infectious TB disease  Yes  No
2. Foreign-born from (or travel\* to/in) a high-prevalence area (e.g., Africa, Asia, Eastern Europe, or Central or South America)  Yes  No
3. Fibrotic changes on a prior chest x-ray suggesting inactive or past TB disease  Yes  No
4. HIV/AIDS  Yes  No
5. Organ transplant recipient  Yes  No
6. Immunosuppressed (equivalent of > 15 mg/day of prednisone for >1 month or TNF- $\alpha$  antagonist)  Yes  No
7. History of high risk illicit drug use  Yes  No
8. Resident, employee, student or volunteer in a high-risk congregate setting (e.g., correctional facilities, nursing homes, homeless shelters, hospitals, and other health care facilities)  Yes  No
9. Medical condition associated with increased risk of progressing to TB disease if infected [e.g., diabetes mellitus, silicosis, head, neck, or lung cancer, hematologic or reticuloendothelial disease such as Hodgkin's disease or leukemia, end stage renal disease, intestinal bypass or gastrectomy, chronic malabsorption syndrome, low body weight (i.e., 10% or more below ideal for the given population)]  Yes  No

\* The significance of the travel exposure should be discussed with a health care provider and evaluated.

1. Is student at high risk for exposure to TB?  Yes  No *If no then TB testing not required proceed to page 4 for signature*
2. Does the student have signs or symptoms of active tuberculosis disease?  Yes  No  
*If YES, proceed with additional evaluation to exclude active tuberculosis disease including TST/IGRA, chest x-ray, and sputum evaluation as indicated. If NO and any previous answers YES proceed with appropriate TB test.*

Name: \_\_\_\_\_  
Last First Middle

DOB: \_\_\_\_/\_\_\_\_/\_\_\_\_  
M D Y

3. Tuberculin Skin Test (TST) (TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write "0". The TST interpretation should be based on mm of induration as well as risk factors.)\*\*

Date Given: \_\_\_\_/\_\_\_\_/\_\_\_\_ Date Read: \_\_\_\_/\_\_\_\_/\_\_\_\_  
Result: \_\_\_\_\_ mm of induration \*\*Interpretation: positive\_\_\_\_ negative\_\_\_\_

(If 2 step test needed complete 2<sup>nd</sup> test 1-3 weeks from first test)  
Date Given: \_\_\_\_/\_\_\_\_/\_\_\_\_ Date Read: \_\_\_\_/\_\_\_\_/\_\_\_\_  
Result: \_\_\_\_\_ mm of induration \*\*Interpretation: positive\_\_\_\_ negative\_\_\_\_

4. Interferon Gamma Release Assay (IGRA)

Date Obtained: \_\_\_\_/\_\_\_\_/\_\_\_\_ (specify method) QFT-G QFT-GIT T-Spot other\_\_\_\_  
Result: negative\_\_\_\_ positive\_\_\_\_ indeterminate\_\_\_\_ borderline\_\_\_\_ (T-Spot only)

Date Obtained: \_\_\_\_/\_\_\_\_/\_\_\_\_ (specify method) QFT-G QFT-GIT T-Spot other\_\_\_\_  
Result: negative\_\_\_\_ positive\_\_\_\_ indeterminate\_\_\_\_ borderline\_\_\_\_ (T-Spot only)

5. Chest x-ray: (Required if TST or IGRA is positive)

Date of chest x-ray: \_\_\_\_/\_\_\_\_/\_\_\_\_ Result: normal\_\_\_\_ abnormal\_\_\_\_

6. TB prevention medication taken:  Yes  No If yes, dates taken: \_\_\_\_/\_\_\_\_/\_\_\_\_ - \_\_\_\_/\_\_\_\_/\_\_\_\_

**\*\*Interpretation guidelines**

**>5 mm is positive:**

- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest x-ray consistent with past TB disease
- Organ transplant recipients
- Immunosuppressed persons: taking > 15 mg/d of prednisone for >1 month; taking a TNF- $\alpha$  antagonist
- Persons with HIV/AIDS

- Persons with the following clinical conditions: silicosis, diabetes mellitus, chronic renal failure, leukemias and lymphomas, head, neck or lung cancer, low body weight (>10% below ideal), gastrectomy or intestinal bypass, chronic malabsorption syndromes

\*The significance of the travel exposure should be discussed with a health care provider and evaluated.

**>10 mm is positive:**

- Persons born in a high prevalence country or who resided in one for a significant\* amount of time
- History of illicit drug use
- Mycobacteriology laboratory personnel
- History of resident, worker, student or volunteer in high-risk congregate settings

**>15 mm is positive:**

- Persons with no known risk factors for TB disease.

ADDITIONAL COMMENTS

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**HEALTH CARE PROVIDER**

SIGNATURE \_\_\_\_\_

ADDRESS \_\_\_\_\_

DATE \_\_\_\_\_

PHONE \_\_\_\_\_

Longwood Reviewer

Date